中等度から重度の活動性クローン病の成人患者に対する経口エトラシモドの有効性と安全性を評価する研究

基本情報

NCT ID

NCT04173273

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

375

治験依頼者名

Pfizer

概要

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension Periods), and the 4-Week Follow-Up Period for safety assessment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)